Long-term survival of endometrioid endometrial cancer patients

Archives of Medical Science

Volumn 6, Issue 6, 2010, Pages 937-944

  Gottwald, Leszek ^a,b   Pluta, Piotr ^a   Piekarski, Janusz ^a   Spych, Michał ^a   Hendzel, Katarzyna ^b   Topczewska Tylinska, Katarzyna ^a   Nejc, Dariusz ^a   Bibik, Robert ^b   Korczyński, Jerzy ^a   Cialkowska Rysz, Ałeksandra ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Disease free survival; Endometrioid endometrial cancer; Overall survival; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; ENDOMETRIOID CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PREGNANCY; PROGNOSIS; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME;

EID: 78751514997     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.19305     Document Type: Article

References (36)

1. Anastasiadis PG, Skaphida PG, Koutlaki NG, et al. Epidemiologic aspects of endometrial cancer in Thrace, Greece. Int J Gynecol Cancer 1999; 66: 263-72.
2. Purdie DM. Epidemiology of endometrial cancer. Reviews in Gynaecological Practice 2003; 3: 217-20.
3. Sonoda Y, Barakat RR. Screening and the prevention of gynecologic cancer: Endometrial cancer. Res Clin Obstet Gyn 2006; 20: 363-77.
4. Ayhan A, Taskiran C, Celik C, et al. Is there a survival benefit to adjuvant radiotherapy in high-risk surgical stage I endometrial cancer? Gynecol Oncol 2002; 86: 259-63.
5. Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: Results from a randomized trial. Gynecol Oncol 2003; 89: 201-9.
6. Preyer O, Obermair A, Formann E, et al. The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with stage IIIA uterine cancer. Gynecol Oncol 2002; 86: 269-73.
7. Carey MS, Gawlik C, Kee-Fung MF, et al. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006; 101: 158-67.
8. Sivridis E. Endometrial adenocarcinoma: An apostasy from early views. Gynecol Oncol 2004; 95: 772-7.
9. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? Int J Radiat Oncol Biol Phys 2002; 54: 79-85.
10. Cirisano FD, Robboy SJ, Dodge RK, et al. Epidemio-pathologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999; 74: 385-94.
11. Pessini SA, Zettler CG, Wender MC, et al. Survival and prognostic factors of patients treated for Stage I to Stage III endometrial carcinoma in a reference cancer center in Southern Brazil. Eur J Gynaecol Oncol 2007; 28: 48-50.
12. Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines for gynaecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obsetet 2000; 70: 209-62.
13. Hirai M, Hirono M, Oosaki T, et al. Prognostic factors relating to survival in uterine endometrioid carcinoma. Int J Gynecol Obstet 1999; 66: 155-62.
14. Pecorelli S, Denny L, Ngan H, et al. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol 2009; 115: 325-8.
15. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1985; 53: 457-81.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
17. Havrilesky LJ, Secord AA, O'Malley DM, et al. Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. Gynecol Oncol 2009; 114: 279-83.
18. Labastida R, Dexeus S, Fábregas R, et al. Endometrial cancer: Factors affecting survival. Eur J Gynaecol Oncol 2003; 24: 381-3.
19. Albrektsen G, Heuch I, Wik E, Salvesen HB. Parity and time interval since childbirth influence survival in endometrial cancer patients. Int J Gynecol Cancer 2009; 19: 665-9.
20. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: Systematic review and meta-analysis. BJOG 2007; 114: 1313-20.
21. Ayhan A, Taskiran C, Celik C, Yuce K. The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol 2004; 93: 9-13.
22. Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001; 82: 371-4.
23. Sartori E, Laface B, Gadducci A, et al. Factors influencing survival in endometrial cancer relapsing patients: A Cooperation Task Force (CTF) study. Int J Gynecol Cancer 2003; 13: 458-65.
24. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group Study. Gynecol Oncol 1991; 40: 55-65.
25. Watanabe Y, Kitanawa R, Aoki D, et al. Practice pattern for postoperative management of endometrial cancer in Japan: A survey of the Japanese Gynecologic Oncology Group. Gynecol Oncol 2009; 115: 456-9.
26. Fung -Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer. A systematic review. Gynecol Oncol 2006; 101: 520-9.
27. Faught W, Krepart GV, Lotocki R, Heywood M. Should selective paraaortic lymphadenectomy be part of surgical staging for endometrial cancer? Gynecol Oncol 1994; 55: 51-5.
28. Mariani A, Webb MJ, Galli L, Podratz C. Potential thera-peutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 2000; 76: 348-65.
29. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway: A study of a total population. Cancer 1991; 67: 3097-103.
30. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma. Cancer 1996; 77: 1115-21.
31. Macdonald OK, Sause WT, Lee RJ, et al. Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: A multi-institutional analysis of 608 women. Gynecol Oncol 2006; 103: 661-6.
32. Bolukbasi Y, Demirci S, Ozsaran Z, et al. Postoperative radiotherapy in intermediate and high-risk Stage I endometrial cancer: Analysis of prognostic factors and survival. Eur J Gynaecol Oncol 2008; 29: 505-10.
33. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology V2 2009 (http://www.nccn.org/ professionals/physiciangls/PDF/uterine. pdf).
34. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2006; 24: 36-44.
35. Aoki Y, Watanabe M, Amikura T, et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol 2004; 94: 333-9.
36. Gottwald L, Lech W, Sobotkowski J, et al. Transvaginal doppler sonography for assessment the response to radiotherapy in locally advanced squamous cervical cancer: A preliminary study. Arch Med Sci 2009; 5: 459-64.